These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16702385)

  • 1. Mesothelin variant 1 is released from tumor cells as a diagnostic marker.
    Hellstrom I; Raycraft J; Kanan S; Sardesai NY; Verch T; Yang Y; Hellstrom KE
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1014-20. PubMed ID: 16702385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
    Scholler N; Fu N; Yang Y; Ye Z; Goodman GE; Hellström KE; Hellström I
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11531-6. PubMed ID: 10500211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
    Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
    Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
    Hassan R; Remaley AT; Sampson ML; Zhang J; Cox DD; Pingpank J; Alexander R; Willingham M; Pastan I; Onda M
    Clin Cancer Res; 2006 Jan; 12(2):447-53. PubMed ID: 16428485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
    Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
    Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
    Shiomi K; Miyamoto H; Segawa T; Hagiwara Y; Ota A; Maeda M; Takahashi K; Masuda K; Sakao Y; Hino O
    Cancer Sci; 2006 Sep; 97(9):928-32. PubMed ID: 16776777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer.
    Muminova ZE; Strong TV; Shaw DR
    BMC Cancer; 2004 May; 4():19. PubMed ID: 15140265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
    Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
    Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
    Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
    Onda M; Nagata S; Ho M; Bera TK; Hassan R; Alexander RH; Pastan I
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4225-31. PubMed ID: 16857795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesothelin is shed from tumor cells.
    Ho M; Onda M; Wang QC; Hassan R; Pastan I; Lively MO
    Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1751. PubMed ID: 16985043
    [No Abstract]   [Full Text] [Related]  

  • 14. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.
    Onda M; Willingham M; Nagata S; Bera TK; Beers R; Ho M; Hassan R; Kreitman RJ; Pastan I
    Clin Cancer Res; 2005 Aug; 11(16):5840-6. PubMed ID: 16115924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.
    Hellstrom I; Friedman E; Verch T; Yang Y; Korach J; Jaffar J; Swisher E; Zhang B; Ben-Baruch G; Tan MC; Goedegebuure P; Hellstrom KE
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1520-6. PubMed ID: 18559570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients.
    Abe H; Kuroki M; Imakiire T; Yamauchi Y; Yamada H; Arakawa F; Kuroki M
    J Immunol Methods; 2002 Dec; 270(2):227-33. PubMed ID: 12379327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
    Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
    Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
    Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
    Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesothelin: a new target for immunotherapy.
    Hassan R; Bera T; Pastan I
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3937-42. PubMed ID: 15217923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.